Seller record · Telehealth service

HealthRX

By Peptide Alliance, Editorial publisherRecorded August 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: Fulfillment is attributed to a licensed 503A pharmacy on the home page and in the footer, and no pharmacy is named. 2 more criteria also fail; see the table below.

At a glance

HealthRXTelehealth service

5/8criteria passed
Price
Semaglutide from $133 a month on a three-month plan
Sells
compounded semaglutide, compounded tirzepatide, and 4 more
FDA letters
None on file
Visit HealthRXSee all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide across a large programmatic library. It publishes no legal entity and no street address.

Operating entity No legal entity name appears in the footer, on the contact page, in the terms or in the privacy policy.

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSHealthRX's website
S2Prescription gatingPASSHealthRX's height weight page
S3Pharmacy identificationFAILHealthRX's website
S4Compounding disclosurePASSHealthRX's website
S5Analytical documentationFAILHealthRX's website
S6Business addressFAILHealthRX's contact page; HealthRX's terms; HealthRX's privacy page
S7Price disclosurePASSHealthRX's website
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSAn independent United States board-certified physician reviews the file within 24 hours and writes a prescription if clinically appropriate.Source: HealthRX's website.
S2PASSThe first intake question, which asks the buyer's goal, stops the order.Source: HealthRX's height weight page.
S3FAILFulfillment is attributed to a licensed 503A pharmacy on the home page and in the footer, and no pharmacy is named.Source: HealthRX's website.
S4PASSCompounded medications are not reviewed or approved by the FDA, stated under the product cards on the home page.Source: HealthRX's website.
S5FAILMedication is described as lot-tracked from the compounding bench to the door, and no lot document is reachable.Source: HealthRX's website.
S6FAILFooter, contact, terms and privacy carry no entity and no address, only a copyright line, an email address and a telephone number.Source: HealthRX's contact page; HealthRX's terms; HealthRX's privacy page.
S7PASSCompounded semaglutide from 133 dollars per month on a three-month plan, and 99 dollars per month on a twelve-month plan.Source: HealthRX's website.
S8PASSNo FDA warning letter names the entity, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, sexual health medications, hair loss medications, NAD+, sermorelin.

Other sellers of the same products

Who sells semaglutideWho sells tirzepatideWho sells sermorelinWho sells NAD+

Visit HealthRX

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.